Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer

Teruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo Imamura, Hideko Yamauchi, Hiromitsu Jinno, Maiko Takahashi, Yuukou Kitagawa, Seigo Nakamura, Bora Lim, Savitri Krishnamurthy, James M. Reuben, Diane Liu, Debasish Tripathy, Helen Chen, Naoko Takebe, Hideyuki Saya, Naoto T. Ueno

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy. In a prospective clinical trial to evaluate pharmacodynamic biomarkers, 18 patients with operable primary HER2-positive breast cancer received dual anti-Her2 preoperative therapy with trastuzumab and lapatinib with paclitaxel. Proportions of tumor cells with CSC characteristics and EMT markers in CTC's were estimated at baseline, after 6 and 18 weeks of preoperative therapy to determine the quantitative cutoff value to predict pathologic complete response (pCR). Out of 18 patients, 8 (44%) had a pCR; 5 of these 8 patients (62%) were positive for CD44v at baseline and none were positive on the 6-week biopsy. In contrast, 6 of the 10 patients without pCR exhibited persistent levels, or enrichment of CD44v proportion and expression at 6 and 18 weeks (p=0.0128). Other biomarkers were not statistically significant predictors of pCR. Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy.

Original languageEnglish
Pages (from-to)6872-6882
Number of pages11
JournalOncotarget
Volume9
Issue number6
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Breast Neoplasms
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Therapeutics
Biomarkers
Phenotype
Circulating Neoplastic Cells
Drug Therapy
Paclitaxel
Neoplasms
Clinical Trials
Biopsy

Keywords

  • Biomarker
  • Breast cancer
  • CD44v
  • HER2
  • Predictive

ASJC Scopus subject areas

  • Oncology

Cite this

Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. / Yamauchi, Teruo; Fernandez, Jose Rodrigo Espinosa; Imamura, Chiyo; Yamauchi, Hideko; Jinno, Hiromitsu; Takahashi, Maiko; Kitagawa, Yuukou; Nakamura, Seigo; Lim, Bora; Krishnamurthy, Savitri; Reuben, James M.; Liu, Diane; Tripathy, Debasish; Chen, Helen; Takebe, Naoko; Saya, Hideyuki; Ueno, Naoto T.

In: Oncotarget, Vol. 9, No. 6, 01.01.2018, p. 6872-6882.

Research output: Contribution to journalArticle

Yamauchi, T, Fernandez, JRE, Imamura, C, Yamauchi, H, Jinno, H, Takahashi, M, Kitagawa, Y, Nakamura, S, Lim, B, Krishnamurthy, S, Reuben, JM, Liu, D, Tripathy, D, Chen, H, Takebe, N, Saya, H & Ueno, NT 2018, 'Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer', Oncotarget, vol. 9, no. 6, pp. 6872-6882. https://doi.org/10.18632/oncotarget.23914
Yamauchi, Teruo ; Fernandez, Jose Rodrigo Espinosa ; Imamura, Chiyo ; Yamauchi, Hideko ; Jinno, Hiromitsu ; Takahashi, Maiko ; Kitagawa, Yuukou ; Nakamura, Seigo ; Lim, Bora ; Krishnamurthy, Savitri ; Reuben, James M. ; Liu, Diane ; Tripathy, Debasish ; Chen, Helen ; Takebe, Naoko ; Saya, Hideyuki ; Ueno, Naoto T. / Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. In: Oncotarget. 2018 ; Vol. 9, No. 6. pp. 6872-6882.
@article{2b1cb783c6d14d82a39a2f85661e92e0,
title = "Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer",
abstract = "Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy. In a prospective clinical trial to evaluate pharmacodynamic biomarkers, 18 patients with operable primary HER2-positive breast cancer received dual anti-Her2 preoperative therapy with trastuzumab and lapatinib with paclitaxel. Proportions of tumor cells with CSC characteristics and EMT markers in CTC's were estimated at baseline, after 6 and 18 weeks of preoperative therapy to determine the quantitative cutoff value to predict pathologic complete response (pCR). Out of 18 patients, 8 (44{\%}) had a pCR; 5 of these 8 patients (62{\%}) were positive for CD44v at baseline and none were positive on the 6-week biopsy. In contrast, 6 of the 10 patients without pCR exhibited persistent levels, or enrichment of CD44v proportion and expression at 6 and 18 weeks (p=0.0128). Other biomarkers were not statistically significant predictors of pCR. Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy.",
keywords = "Biomarker, Breast cancer, CD44v, HER2, Predictive",
author = "Teruo Yamauchi and Fernandez, {Jose Rodrigo Espinosa} and Chiyo Imamura and Hideko Yamauchi and Hiromitsu Jinno and Maiko Takahashi and Yuukou Kitagawa and Seigo Nakamura and Bora Lim and Savitri Krishnamurthy and Reuben, {James M.} and Diane Liu and Debasish Tripathy and Helen Chen and Naoko Takebe and Hideyuki Saya and Ueno, {Naoto T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23914",
language = "English",
volume = "9",
pages = "6872--6882",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer

AU - Yamauchi, Teruo

AU - Fernandez, Jose Rodrigo Espinosa

AU - Imamura, Chiyo

AU - Yamauchi, Hideko

AU - Jinno, Hiromitsu

AU - Takahashi, Maiko

AU - Kitagawa, Yuukou

AU - Nakamura, Seigo

AU - Lim, Bora

AU - Krishnamurthy, Savitri

AU - Reuben, James M.

AU - Liu, Diane

AU - Tripathy, Debasish

AU - Chen, Helen

AU - Takebe, Naoko

AU - Saya, Hideyuki

AU - Ueno, Naoto T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy. In a prospective clinical trial to evaluate pharmacodynamic biomarkers, 18 patients with operable primary HER2-positive breast cancer received dual anti-Her2 preoperative therapy with trastuzumab and lapatinib with paclitaxel. Proportions of tumor cells with CSC characteristics and EMT markers in CTC's were estimated at baseline, after 6 and 18 weeks of preoperative therapy to determine the quantitative cutoff value to predict pathologic complete response (pCR). Out of 18 patients, 8 (44%) had a pCR; 5 of these 8 patients (62%) were positive for CD44v at baseline and none were positive on the 6-week biopsy. In contrast, 6 of the 10 patients without pCR exhibited persistent levels, or enrichment of CD44v proportion and expression at 6 and 18 weeks (p=0.0128). Other biomarkers were not statistically significant predictors of pCR. Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy.

AB - Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes correlate to response to dual anti-HER2 therapy. In a prospective clinical trial to evaluate pharmacodynamic biomarkers, 18 patients with operable primary HER2-positive breast cancer received dual anti-Her2 preoperative therapy with trastuzumab and lapatinib with paclitaxel. Proportions of tumor cells with CSC characteristics and EMT markers in CTC's were estimated at baseline, after 6 and 18 weeks of preoperative therapy to determine the quantitative cutoff value to predict pathologic complete response (pCR). Out of 18 patients, 8 (44%) had a pCR; 5 of these 8 patients (62%) were positive for CD44v at baseline and none were positive on the 6-week biopsy. In contrast, 6 of the 10 patients without pCR exhibited persistent levels, or enrichment of CD44v proportion and expression at 6 and 18 weeks (p=0.0128). Other biomarkers were not statistically significant predictors of pCR. Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy.

KW - Biomarker

KW - Breast cancer

KW - CD44v

KW - HER2

KW - Predictive

UR - http://www.scopus.com/inward/record.url?scp=85040915684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040915684&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23914

DO - 10.18632/oncotarget.23914

M3 - Article

AN - SCOPUS:85040915684

VL - 9

SP - 6872

EP - 6882

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -